BeiGene Gains US OK to Start Trial of Cancer Drug

BeiGene, a Beijing biopharma focused on cancer therapies, was granted FDA approval to begin US clinical trials of BGB-3111, its proprietary Bruton tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies. In preclinical tests, BGB-3111 showed improved efficacy and a better safety profile than existing BTK inhibitors, said BeiGene. BTK plays a part in B-cell receptor signaling, which is significant for B-cell malignancies such as various forms of leukemia. More details.... Share this with colleagues: // //